MX9201969A - Formulacion de tableta optimizada. - Google Patents

Formulacion de tableta optimizada.

Info

Publication number
MX9201969A
MX9201969A MX9201969A MX9201969A MX9201969A MX 9201969 A MX9201969 A MX 9201969A MX 9201969 A MX9201969 A MX 9201969A MX 9201969 A MX9201969 A MX 9201969A MX 9201969 A MX9201969 A MX 9201969A
Authority
MX
Mexico
Prior art keywords
tablet formulation
optimized
optimized tablet
formulation
tablet
Prior art date
Application number
MX9201969A
Other languages
English (en)
Inventor
Ashok V Katdare
John C Cunningham
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MX9201969A publication Critical patent/MX9201969A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX9201969A 1991-04-29 1992-04-28 Formulacion de tableta optimizada. MX9201969A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69274791A 1991-04-29 1991-04-29

Publications (1)

Publication Number Publication Date
MX9201969A true MX9201969A (es) 1992-11-01

Family

ID=24781844

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9201969A MX9201969A (es) 1991-04-29 1992-04-28 Formulacion de tableta optimizada.

Country Status (15)

Country Link
EP (1) EP0511767A1 (es)
JP (1) JPH06157309A (es)
KR (1) KR920019340A (es)
CN (1) CN1066184A (es)
AU (1) AU1522992A (es)
CA (1) CA2067307A1 (es)
CZ (1) CZ227093A3 (es)
IE (1) IE921384A1 (es)
IL (1) IL101679A0 (es)
MX (1) MX9201969A (es)
NO (1) NO933806L (es)
NZ (1) NZ242486A (es)
SK (1) SK117793A3 (es)
WO (1) WO1992019228A1 (es)
ZA (1) ZA923068B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
ES2154744T3 (es) * 1994-12-14 2001-04-16 Enbalt Trading Ltd Formulaciones de comprimidos farmaceuticos para compresion directa.
EP0910375B1 (en) * 1996-06-24 2002-05-02 Merck & Co., Inc. A composition of enalapril and losartan
WO2000032191A1 (en) * 1998-12-01 2000-06-08 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
DK1708690T3 (en) 2003-11-17 2016-11-07 Biomarin Pharm Inc TREATMENT OF PHENYLKETONURI WITH BH4
RU2007115900A (ru) 2004-10-27 2008-11-10 Дайити Санкио Компани, Лимитед (Jp) Производные бензола, имеющие 2 или более заместителей
CA2609026A1 (en) * 2005-05-18 2007-03-08 Combino Pharm, S.L. Formulations containing losartan and/or its salts
HUE049976T2 (hu) 2005-12-28 2020-11-30 Vertex Pharma N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
JP2008208078A (ja) * 2007-02-27 2008-09-11 Takada Seiyaku Kk 分割錠剤
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR112014021090B1 (pt) 2012-02-27 2023-01-24 Vertex Pharmaceuticals Incorporated Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
CN105395509A (zh) * 2015-12-16 2016-03-16 宁波美诺华天康药业有限公司 一种氯沙坦钾片的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670251A (en) * 1984-05-30 1987-06-02 Igene Biotechnology, Inc. Microcrystalline tableting excipient derived from whey
US4753801A (en) * 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles

Also Published As

Publication number Publication date
NO933806L (no) 1993-10-22
WO1992019228A1 (en) 1992-11-12
ZA923068B (en) 1992-12-30
IL101679A0 (en) 1992-12-30
CA2067307A1 (en) 1992-10-30
CN1066184A (zh) 1992-11-18
NZ242486A (en) 1993-12-23
KR920019340A (ko) 1992-11-19
SK117793A3 (en) 1994-05-11
CZ227093A3 (en) 1994-03-16
EP0511767A1 (en) 1992-11-04
JPH06157309A (ja) 1994-06-03
IE921384A1 (en) 1992-11-04
AU1522992A (en) 1992-11-05

Similar Documents

Publication Publication Date Title
FI921060A0 (fi) Farmaceutiska aerosolformuleringar.
FI922958A0 (fi) Farmaceutisk sammansaettning.
FI922252A0 (fi) Farmaceutisk sammansaettning.
FI922316A0 (fi) Farmaceutisk sammansaettning.
FI923581A0 (fi) Farmaceutisk kombinationsformation.
FI921924A0 (fi) Portabel koldioxidmonitor.
MX9201969A (es) Formulacion de tableta optimizada.
TR27454A (tr) Tablet dagitici düzenek.
DE59201883D1 (de) Tilger.
FR2683649B1 (fr) Tablette digitalisante.
FI923371A0 (fi) En farmaceutisk formulation.
MX9201791A (es) Medicamentos.
ES1016291Y (es) Pulverizador-divisor de comprimidos.
FI914237A0 (fi) Kontinuerligt badfaerdig bastuugn.
FI912646A0 (fi) Regel/gaongjaern.
MX9206975A (es) Composicion farmaceutica.
MX9101420A (es) Poliera estansal. poliera estansal.
ES1018322Y (es) Hidrocompresor.
ES1016842Y (es) Carpeta-agenda.
ES1018708Y (es) Batidora-mezcladora.
ES1018836Y (es) Cisterna-remolque.
ES1019520Y (es) Lapida funeraria.
ES1015938Y (es) Pizarro-calendario.
ES1016478Y (es) Papelera pefeccionada.
ES1018067Y (es) Tarjeta-puzzle.